InvestorsHub Logo
Followers 99
Posts 2761
Boards Moderated 2
Alias Born 02/10/2004

Re: Medtrade77 post# 19355

Tuesday, 11/12/2019 1:33:11 PM

Tuesday, November 12, 2019 1:33:11 PM

Post# of 19499
Anyone buying this should also be made aware of the Bankruptcy filing indicating that Class 6 Creditors (Insiders) hold a $1,266,849 convertible note that could be converted at a 45% discount to the market. It's discussed in Section 4.8 of the Exhibits filed with the SEC here:
https://www.bamsec.com/filing/161577418007286/3?cik=844985

That could be some significant dilution from our current low O/S. With the current share price @ $0.14, the 45% discount would price shares @ $0.077, which would amount to 16,542,545 shares being issued (not accounting for any interest on the note).

I've been told the note holders are "friendly" to current shareholders, appreciate the value of tight capital structure, and are not going to look to play manipulative games with the stock price prior to conversion.

All that being said, I still really like this company's potential once Lantheus's Flurpiridaz F-18 imaging agent gets approval, which is expected in about a year, and will probably give PET a distinctive advantage over SPECT for imaging accuracy/price/ and half life (allowing exercise induced stress):
http://www.lantheus.com/pipeline/flurpiridaz-f-18/

"Our houses are such unwieldy property that we are often imprisoned rather than housed in them." - Henry David Thoreau, Walden: Economy, 1854